Nature medicine publishes results from pivotal phase 3 lavender™ study evaluating daybue™ (trofinetide) efficacy and safety in patients with rett syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that nature medicine published results from the pivotal phase 3 lavender™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daybue™ in patients with rett syndrome five to 20 years of age. “the lavender study was designed to measure the effect of daybue treatment on the range of behavioral, communication, and physical rett syndrome symptoms that significa.
ACAD Ratings Summary
ACAD Quant Ranking